375 related articles for article (PubMed ID: 29215041)
1. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
[TBL] [Abstract][Full Text] [Related]
4. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
[TBL] [Abstract][Full Text] [Related]
6. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
7. Different Methods of Delivering CRISPR/Cas9 Into Cells.
Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of viral vectors as vehicles for DMD gene editing.
Maggio I; Chen X; Gonçalves MA
Genome Med; 2016 May; 8(1):59. PubMed ID: 27215286
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
10. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
12. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
13. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
[TBL] [Abstract][Full Text] [Related]
14. Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice.
Xu L; Gao Y; Lau YS; Han R
J Vis Exp; 2018 Aug; (138):. PubMed ID: 30124643
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas9 technology and its application in haematological disorders.
Zhang H; McCarty N
Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
[TBL] [Abstract][Full Text] [Related]
16. Viral Delivery Systems for CRISPR.
Xu CL; Ruan MZC; Mahajan VB; Tsang SH
Viruses; 2019 Jan; 11(1):. PubMed ID: 30621179
[TBL] [Abstract][Full Text] [Related]
17. In vitro CRISPR-Cas9-mediated efficient Ad5 vector modification.
Tang L; Gong M; Zhang P
Biochem Biophys Res Commun; 2016 May; 474(2):395-399. PubMed ID: 27125457
[TBL] [Abstract][Full Text] [Related]
18. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-mediated correction of human genetic disease.
Men K; Duan X; He Z; Yang Y; Yao S; Wei Y
Sci China Life Sci; 2017 May; 60(5):447-457. PubMed ID: 28534256
[TBL] [Abstract][Full Text] [Related]
20. Chromatin accessibility and guide sequence secondary structure affect CRISPR-Cas9 gene editing efficiency.
Jensen KT; Fløe L; Petersen TS; Huang J; Xu F; Bolund L; Luo Y; Lin L
FEBS Lett; 2017 Jul; 591(13):1892-1901. PubMed ID: 28580607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
